Furthermore, we have selected a large group of primary care practices to ensure a diverse patent population and have taken active steps to reduce a variety of potential biases through the use of randomisation procedures.
For over two decades, Munich has had Germany's highest share of technology patents by population.
In addition, exposure to riociguat in patients with PAH-CHD was generally comparable with that in patients with other PAH aetiologies in the PATENT-1 population.
In particular, at week 12, riociguat 2.5 mg maximum decreased NT-proBNP levels from baseline by 164 pg/mL in the PAH-CHD subgroup, compared with a decrease of 198 pg/mL in the overall PATENT-1 population.
An analysis of the pharmacokinetics of riociguat showed comparable area under the plasma concentration time curve and maximum plasma concentration between patients with PAH-CHD and patients with other PAH aetiologies in the PATENT-1 population (figure 3A, B).
During the peak transmission season up to 35% of the population had patent parasitemia with 8 10% infected with ≥2 parasite strains.
Under baseline conditions (prior to interventions) with an EIR of ∼3 (low transmission), 12 15% of the population had patent parasitemia at the peak of the transmission season with <1% of individuals having multiple infections.
Only Slovenia, with 42 patents per 1m population in the 2000-2003 period, comes anywhere close to the western European average of 200.
19 In this study, the improvements in PVR, mPAP, right atrial pressure and cardiac index seen with riociguat 2.5 mg maximum in the PAH-CHD subgroup were similar to those observed in the overall PATENT-1 study population.
Ultimately, the initial goal of the BPCA was to establish a process for studying on-patent and off-patent drugs for use in pediatric populations.
